Medexus Pharmaceuticals
Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.
Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. They leverage the innovative ADAPTIR™ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.Based in Seattle, Washington, the company is proud of its empowering work environment, entrepreneurial culture, and proprietary platform technology. As a result, Aptevo has been able to attract some of the most innovative minds in the field. Many of our team members have notable experience with other pioneering biotech companies including Trubion, ZymoGenetics, Immunex, Dendreon, and VLST.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.